APYX Sees 3-30% Revenue Growth, AVDL Awaits FDA Decision, KZR To Report MISSION Data In Q2...

Kezar Life Sciences Inc (KZR) has a couple of catalysts to watch in the coming months. Topline data from its MISSION and PRESIDIO trials are expected in the second quarter of this year. Will Kezar accomplish its mission?

from RTT - Top Story https://ift.tt/62ojXOd
via IFTTT